Loading
Urologist who led the CCGA study validating the Galleri methylation-based multi-cancer detection test.
Eric Klein led the Circulating Cell-free Genome Atlas (CCGA) study that developed and clinically validated the Galleri cell-free DNA methylation test for detecting more than 50 cancer types and predicting tissue of origin, the basis for the PATHFINDER and NHS-Galleri trials. As a urologist he led the SELECT prevention trial and the development of the Oncotype DX prostate score.
Shares PATHFINDER 2, PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms, Galleri, NHS-Galleri and the tags early-detection, mced.
Shares Multi-cancer early detection (MCED) and the tags early-detection, mced.
Shares PATHFINDER 2, NHS-Galleri, Multi-cancer early detection (MCED), DNA methylation profiling.
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares PATHFINDER 2, Galleri, NHS-Galleri, Multi-cancer early detection (MCED).
Shares Galleri, Annals of Oncology, Multi-cancer early detection (MCED), DNA methylation profiling.